Compare MNDR & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNDR | POAI |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.5M |
| IPO Year | 2024 | N/A |
| Metric | MNDR | POAI |
|---|---|---|
| Price | $1.77 | $5.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.9M | 27.4K |
| Earning Date | 10-31-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,646,739.00 | $1,664,407.00 |
| Revenue This Year | $608,852.40 | $486.27 |
| Revenue Next Year | N/A | $65.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 320.71 |
| 52 Week Low | $1.53 | $4.76 |
| 52 Week High | $40.00 | $45.90 |
| Indicator | MNDR | POAI |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 35.22 |
| Support Level | $1.85 | $5.31 |
| Resistance Level | $2.92 | $6.00 |
| Average True Range (ATR) | 0.55 | 0.55 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 6.43 | 7.16 |
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services, and the Sale of medicine and medical devices. The majority of the company's revenue is derived from the Telemedicine and other services segment. Geographically, it derives revenue from Singapore.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.